| Autor: |
Gungor B; Department of Biological Sciences; Middle East Technical University ; Ankara, Turkey., Yagci FC; Department of Molecular Biology and Genetics Bilkent University ; Ankara, Turkey., Gursel I; Department of Molecular Biology and Genetics Bilkent University ; Ankara, Turkey., Gursel M; Department of Biological Sciences; Middle East Technical University ; Ankara, Turkey. |
| Jazyk: |
angličtina |
| Zdroj: |
Oncoimmunology [Oncoimmunology] 2014 Jul 03; Vol. 3 (7), pp. e950166. Date of Electronic Publication: 2014 Jul 03 (Print Publication: 2014). |
| DOI: |
10.4161/21624011.2014.950166 |
| Abstrakt: |
Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFNα) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
